Primary carcinoma of the vagina (PCV) is a rare malignancy, comprising only 1-2% of the malignancies of the female genital tract (Beller et al, 2006) . The most prevalent histological type of PCV is squamous cell carcinoma (SCC). Primary carcinoma of the vagina mostly affects women over 60 years of age and has a poor prognosis (Beller et al, 2006; Hellman et al, 2006) . Due to its rarity, biological and prognostic factors of PCV have not been frequently studied, in contrast to other malignancies of the female genital tract.
The importance of human papillomavirus (HPV) and its oncogenic potential in the female genital tract, as well as in the oropharynx, has received considerable attention in the last decades. In accordance with other SCCs of the genital tract, such as cervical, vulvar, and anogenital carcinoma, the majority of PCV is associated with high-risk HPV types, with a reported range of 51.4-81% (Insinga et al, 2008; De Vuyst et al, 2009; Smith et al, 2009; Fuste et al, 2010; Brunner et al, 2011; Alonso et al, 2012) . Two ethiopathogenic pathways have been postulated for PCV: one related to high-risk HPV positive, and the other to high-risk HPVnegative PCV (Koyamatsu et al, 2003; Hellman et al, 2004; Fuste et al, 2010; Alonso et al, 2012) . Knowledge of HPV status is important in PCV because of its suggested clinical and prognostic significance (Brunner et al, 2011; Alonso et al, 2012) , but HPV status is also important in understanding the aetiology of PCV.
When HPV integrates in the host cell genome in squamous cells, the result is overexpression of the viral oncogenic proteins E6 and E7, which interact with a number of specific cellular proteins to initiate neoplastic transformation. The E7 protein binds to the tumour suppressor protein, retinoblastoma gene product (pRB), leading to upregulation of CDKs, degradation of pRB, and enhanced expression of p16 INK4A . Thus, an oncogenic HPV infection results in an accumulation of p16 INK4A in the cell's nucleus and cytoplasm (Klaes et al, 2001) . p16
INK4A expression measured by immunohistochemistry may be useful in clinical application as an indicator of degraded pRB caused by overexpression of the E7 protein. Studies in other SCCs have shown that p16 INK4A expression measured by immunohistochemistry correlates well with HPV positivity (Mellin Dahlstrand et al, 2005; Santos et al, 2006; Reimers et al, 2007; Fuste et al, 2010) , making it a useful biomarker for HPV-related oncogenic activity and malignant transformation in cervix, vulva, and vagina (Klaes et al, 2001; O'neill and Mccluggage, 2006; Fuste et al, 2010) . In the cervix p16
INK4A has proven as useful in identifying dysplasia, and correlates with the severity of dysplasia (Norman et al, 2007) . In the cervix and other sites, it has also been demonstrated to be of prognostic significance (Masoudi et al, 2006; Reimers et al, 2007; Schwarz et al, 2012) .
Ki-67 is a proliferation antigen, which is expressed in the nuclei of growing cells. It is used to assess the proliferation index of a cell population and can be used for grading dysplasia in cervical biopsies (Baak and Kruse, 2005) . MIB-1 staining is reduced in atrophy and increased in dysplasia (Mittal et al, 1999) , making it useful in histopathologically uncertain cases as it can help distinguish between postmenopausal changes and dysplasia. It has been suggested that higher MIB-1 immunostaining intensity is an indicator of increased proliferation activity, which is associated with unfavourable clinical outcome, increased tumour size, and more advanced stage of cancer (Heatley 1998; Kruse et al, 2003) . In cervical adenocarcinoma, increased Ki-67 expression was seen in tumours of lower grade and tumours with a higher stage at diagnosis, and correlated with a worse prognosis (Muller et al, 2008) . It was observed that Ki-67 expression had a similar prognostic value in vulvar carcinoma (Hantschmann et al, 2000) . Increased Ki-67 expression in PCV has previously been demonstrated, but has not been associated with survival (Koyamatsu et al, 2003; Habermann et al, 2004; Hellman et al, 2013) .
Many prognostic factors for PCV have been studied, including tumour stage, tumour size, and women's age (Habermann et al, 2004; Hellman et al, 2006; Brunner et al, 2011; Jang et al, 2012) . Human papillomavirus-positive PCV has a better prognosis than HPV-negative PCV in early stages (Alonso et al, 2012) . p16 INK4A expression measured by immunohistochemistry may be used to determine the HPV status of PCV (Fuste et al, 2010; Alonso et al, 2012) . Prognostic factors and biomarkers of PCV need to be further elucidated to improve diagnostic tools and treatment. The aim of this study is to determine HPV status and to investigate p16 INK4A and Ki-67 expression and their correlation with clinical parameters and survival in patients with PCV.
MATERIALS AND METHODS
Patients and tumour biopsies. This study is based on a population of 130 consecutive patients who were diagnosed with PCV, and subsequently treated at Karolinska University Hospital between 1978 and 1995. To get two groups with a significant difference in survival, patients with PCV were divided into short-term survivors (dying within p2 years of diagnosis) and long-term survivors (surviving X8 years after diagnosis). Of the 130 consecutive patients, 77 fell into one of the two defined groups. Archived tumour biopsies from these 77 patients were examined at the Department of Pathology, Karolinska University Hospital. All tumour biopsies were fixed in buffered formaldehyde, paraffinembedded and diagnosed on haematoxylin and eosin-stained tissue sections.
For the present study, four sections from each archived tumour biopsy were prepared and used for histological diagnosis and immunohistochemistry (thickness: 4 mm). Sections for haematoxylin and eosin staining were prepared before and after each section to confirm tumour representativity. Primary carcinoma of the vagina diagnoses, as well as the representativity of the sections used for immunohistochemical studies, were reviewed and confirmed by two pathologists (C Silfversward and E Wilander) Nine tumour biopsies were excluded due to poor material with necrosis. Thus, 68 patients with PCV, 39 short-term and 29 long-term survivors, were included in the final analyses. Sixty-three tumour biopsies were classified as SCC, two as adenocarcinoma, and three as small cell carcinoma (Table 1 ). The study protocol was accepted by the ethical committee of the Stockholm County Council . Patient permission for use of archived tumour biopsies was not required.
Fifty-one patients received a combination of external beam irradiation and brachytherapy, eleven patients received only brachytherapy, and six patients were treated with surgery and/or chemotherapy alone. The medium external dose was 40 Gy (range 19-60 Gy) and the medium dose to the vaginal tumour was 57 Gy (range 14-100 Gy). Patients were followed up at 4-month intervals for 2 years and at 6-month intervals thereafter for an additional 3 years. After 5 years, patients were referred to a general gynaecologist for annual follow-up. All patients included in the study had a reliable documented follow-up, with a minimum of 8 years for the long-term survivors (Table 2) .
Recurrence was defined as disease reappearance 3 months or more after completion of primary treatment in a patient considered to be in complete remission. Evidence of disease o3 months after completion of treatment was defined as persistent disease (Table 2) .
HPV status. Briefly, analyses were performed on extracted DNA obtained from a 10-mm thick section of paraffin blocks, the preceding section of which had been used for morphological diagnosis. These sections of archived tumour biopsies were dewaxed with xylene-ethanol. DNA was extracted by a MagNA Pure LC Robot (Roche Diagnostics, Basel, Switzerland) according to the manufacturer's instructions.
HPV detection and typing. The quality of DNA samples was analysed using a b-globin real-time PCR using 1 ml of the sample. All samples that we included for future analysis were b-globin positive. Human papillomavirus testing was performed by PCR amplification of a fragment in the L1 gene. Samples were tested for the presence of HPV DNA by amplifying 1 ml of DNA with the MGP primer system as previously described (Soderlund-Strand et al, 2009). The Bioplex 200 Luminex system (Bio-Rad, Hercules, CA, USA) was used for HPV detection and genotyping using multiplex bead-based hybridisation with Luminex technology as described by Schmitt et al (2006) . Briefly, 10 ml of the biotinylated MGP-PCR product was mixed with beads coupled with different HPV probes. After 10 min of denaturation at 95 1C, the samples were hybridised at 41 1C for 30 min. After washing, streptavidin-Rphycoerythrin was incubated with the samples for 30 min at room temperature. One hundred beads of each HPV type from each sample were analysed using the Luminex system. Probes for 14 oncogenic, high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68a , and 68b, including probes for variant sequences of HPV18, 35, 51, and 58) and 22 non-oncogenic types including low-risk and possible high-risk types (6, 11, 26, 30, 40, 42, 43, 53, 54, 61, 67, 70, 73, 74, 81, 82, 83, 86, 87, 89, 90 , and 91) were used. Eleven negative controls (H 2 O) and eight positive controls (HPV plasmid pools) were included in each test.
Immunohistochemistry for p16
INK4A and MIB-1. Immunohistochemical staining was performed with the CINtec Histology Kit (Code No. K5336; DAKO Cytomation, Glostrup, Denmark) according to the manufacturer's recommendations using the Dako Autostainer. This kit contains Tris EDTA buffer ( Â 10) pH 9, intended for epitope retrieval. A Coplin jar filled with epitope retrieval buffer, diluted 1 : 10 with distilled water, was placed in a water bath and heated to 95-99 1C. Deparaffinised sections were then incubated for 10 min while maintaining a temperature of 95-99 1C. Jars with slides were removed from the water bath and left to cool at room temperature for 20 min, followed by washing for 5 min in Wash Buffer (Code No. S3006; DAKO Cytomation) diluted 1 : 10 with distilled water. The automated procedure began with 1 Â rinse (1 Â rinse equals 4 min) in wash buffer diluted 1 : 10 with distilled water (Wash Buffer ( Â 10), Code No. S3006; DAKO Cytomation). Endogenous peroxidase activity was abolished by incubating slides for 5 min in a peroxidase-blocking solution (Dako REAL, Code No. S2023; DAKO Cytomation). Slides were rinsed 1 Â , after which 200 ml of the primary antibody against the p16 INK4a protein clone E6H4 was dropped onto each slide, followed by incubation for 30 min. Slides were rinsed 1 Â . Reaction products were visualised by incubating slides for 30 min with a visualisation reagent (a horseradish peroxidase/goatanti-mouse immunoglobulin-labelled dextran polymer) and, after 2 Â rinses, incubated for 10 min in a 1 : 40 solution of DAB chromogen (3.3 0 -diaminobenzidine) in DAB buffered substrate, also from the CINtec Histology Kit. Slides were then washed in distilled water for 1 min and counterstained for 2 min in Harris Hematoxylin solution diluted 1 : 2 with distilled water. After 2 min of washing in water, slides were dehydrated in ethanol to xylene and mounted in a water-free permanent mounting medium with mounting glass. Tissue sections containing cervical cancer were used as positive controls for p16 INK4a , while negative controls consisted of incubated doublet slides in the negative control reagent contained in the kit, instead of primary antibodies.
Immunostaining was independently evaluated by two observers (C Flores-Staino and E Wilander) and was considered as positive for p16
INK4a when both observers agreed that the nuclei were clearly stained. In addition, cells with a distinct cytoplasmic immunoreaction were scored as positive. Image analysis was carried out as previously described. Immunohistochemistry results were scored based on both staining intensity and percentage of immunoreactive epithelial cells (Sano et al, 1998; Klussmann et al, 2003) . Scoring criteria for p16
INK4a were no expression (negative); weak expression (o30% positive cells); moderate expression (31-50% positive cells); and strong expression (450% positive cells). Samples scored as moderate or higher were considered as positive for p16
INK4a (Sano et al, 1998; Klussmann et al, 2003) . To detect the Ki-67 antigen, we used the monoclonal mouse antibody (clone MIB-1) (Code No. M7240; DAKO Cytomation). The Ki-67 antigen is a marker for mitotically active cells and is expressed in the nuclei of growing cells. Tumour biopsy sections were deparaffinised, rehydrated, and microwave treated in target retrieval solution diluted 1 : 10 with distilled water (Dako REAL Target Retrieval Solution ( Â 10) Code No. S2023; DAKO Cytomation) for 2 Â 5 min at 500 W. Thereafter, slides were subjected to the autostainer procedure and treated together with the p16
INK4a slides as described above. Ki-67 positivity was scored with respect to nuclear staining and with attention to heterogeneity in distribution as follows: o10% positive cells; 10-50% positive cells; and 450% positive cells.
Statistical analysis.
Associations between ordinal variables were tested using the Chi-square test or the Fisher's exact test. When investigating possible correlations between immunohistochemical staining and clinical parameters, the semi-quantitative groups described above were analysed with Spearman's rank correlation coefficients.
In the multivariate analyses, the median value was used to generate two groups of equal size for the immunohistochemical staining of Ki-67, with a cutoff at 50% positive cells. All parameters that showed a significant difference when comparing short-and long-term survivors were then included in a multivariate logistic regression model to evaluate the independence of each factor. The median age in different groups was compared using the Mann-Whitney test.
The covariates used in the statistical analysis are described in Table 1 .
RESULTS

Immunohistochemical expression of p16
INK4A in relation to clinical parameters and HPV status. Seven patients with PCV (10.3%) had no p16 INK4A expression, eight (11.7%) had weak expression, sixteen (23.5%) had moderate expression, and thirtyseven (54.4%) had strong expression. A significant correlation was detected between p16 INK4A expression and histopathological grade, HPV status, and survival (Table 3). Increasing p16 INK4A expression correlated significantly with moderately and poorly differentiated tumours (P ¼ 0.004). Furthermore, higher p16
INK4A expression correlated significantly with long-term survival (P ¼ 0.045, Spearman correlation À 0.24). Patients with moderate/high expression of p16 INK4A had better survival if the tumours were HPV negative compared with HPV-positive tumours (P ¼ 0.028), data not shown.
All patients with regional or distant metastasis had moderate or strong p16 INK4A expression; however, this was not significant due to the small number of patients that had metastasis. Patients with strong p16 INK4A expression were younger than those with weak p16 INK4A expression, although this difference was not significant. There was no correlation between relapse and the expression of p16.
Immunohistochemical expression of Ki-67 in relation to clinical parameters. Seven patients with PCV (10.3%) had o10% Ki-67-positive cells, 38 (55.9%) had 10-50% positive cells, and 23 (33.8%) had 450% positive cells. A significant correlation between Ki-67 expression and histopathological grade (Po0.001) and tumour size (P ¼ 0.047) was found (Table 4) . However, there was no correlation detected between Ki-67 expression and long-and short-term survival or relapse.
HPV types and status in correlation with clinical parameters and expression of p16
INK4A and Ki-67. Forty-four out of sixty-eight patients with PCV could be evaluated for HPV status. Nineteen (43%) were positive for high-risk HPV and twenty-five (57%) were HPV negative ( Table 5 ). The majority (12 out of 19, 63%) of HPV-positive patients were positive for HPV16. The others were positive for HPV45 (3 patients, 16%), HPV18
(1 patient, 5.3%), HPV35 (1 patient), HPV56 (1 patient), and HPV68 (1 patient expression. In all, 3 out of the 25 HPV-negative patients (12%) were negative for p16 INK4A immunostaining, while the remaining 88% showed varying expression: 17 out of 25 (68%) showed moderate or strong p16
INK4A expression. All HPV-positive patients with PCV showed moderate to strong proliferation activity; however, there was no significant correlation between Ki-67 expression and HPV status ( Table 4) .
The mean age of HPV-positive and HPV-negative patients was 72 years (range 51-89) and 68 years (range 32-84), respectively (Table 6 ). Hysterectomy was reported by 8 out of 19 HPV-positive patients (42%), and 9 out of 25 (36%) HPV-negative patients. There was no difference in HPV positivity among women with a history of CIN (seven HPV positive and nine HPV negative) or hysterectomy (eight HPV positive and nine HPV negative). Seven HPV-positive patients (7 out of 19, 37%) underwent hysterectomy due to CIN 0-6 years before PCV diagnosis. Five HPV-negative patients with PCV (5 out of 25, 20%) underwent hysterectomy due to CIN 1-9 years before PCV diagnosis.
All of the HPV-positive patients with PCV had moderate to poor histopathological grade (P ¼ 0.011). The two adenocarcinomas were negative for HPV and had low expression of p16. Only one of the three small cell carcinomas was evaluable for HPV and that case was negative with moderate expression of p16. The other two small cell carcinomas showed high expression of p16. Human papillomavirus-positive patients were diagnosed at more advanced stages and the tumour was more commonly localised in the upper third of the vagina. The growth pattern was more often ulcerative in HPV-positive patients and exophytic in HPV-negative patients, but this difference was not statistically significant. No significant difference was seen in survival or relapse by HPV status.
Survival analyses. Reliable follow-up data were available for all 68 patients with PCV. In the univariate analysis, there was a significant correlation between higher p16
INK4A expression and long-term survival (Table 4) . Larger tumour size and higher FIGO stage correlated negatively with survival (Table 7) . Locally advanced tumours with growth in the septum rectovaginale correlated significantly with short-term survival (P ¼ 0.030). In the multivariate analysis, the presence of local metastasis could not be included since there were no long-term survivors with local metastasis. The FIGO stage was also excluded from the analysis since it did not add any additional influence after tumour size was included. Thus, the parameters included in the analysis were histopathological grade, tumour size, Ki-67 expression, and p16
INK4A
expression. Small tumour size and low histopathological grade remained statistically significantly associated with long-term survival, whereas Ki-67 expression and p16 INK4A expression did not.
DISCUSSION
In this study, HPV status and the expression of molecular markers p16 INK4A and Ki-67 were evaluated as prognostic markers in 68 patients diagnosed with PCV. There are some limitations to our study that should be addressed. This study was retrospective and relied on archived tumour biopsies that were 410 years old. On the other hand, the study was based on one of the largest collections of biological material in the literature to-date on HPV and biological markers for this rare disease. Other studies addressing the prognostic value of HPV in PCV have included 35-69 patients (Brunner et al, 2011; Alonso et al, 2012; Larsson et al 2013) , thus our study are among the larger ones.
Ki-67 expression correlated with histopathological grade and tumour size, and p16
INK4A
expression correlated with INK4A expression and the presence of HPV DNA. It has previously been reported that HPV is a positive prognostic factor in PCV (Brunner et al, 2011; Alonso et al, 2012; Larsson et al, 2013) ; p16
INK4A expression was investigated in one of these studies (Alonso et al, 2012) and was not a marker for survival. Thus, the role of p16 INK4A expression as a marker for survival in PCV is still unclear. The inconsistent results might be explained by the limited number of patients included in both studies, and also by the different methods used to evaluate p16 INK4A expression. In both studies, there was a clear correlation between p16
INK4A expression and HPV status. In our study, HPV status could only be evaluated in 65% of the patients, which could be one reason why we found no prognostic value. Likewise, Brunner et al (2011) found that prognosis did not significantly differ between HPV-positive and HPV-negative tumours in the entire cohort; however, patients with unfavourable tumour stage and HPV positivity had improved disease-free and overall survival. In multivariate analysis, Alonso et al (2012) confirmed better disease-free and overall survival of HPV-positive patients independent of age and stage. This reduced risk of progression and mortality in HPV-positive patients was limited to patients with stage I and II tumours.
Human papillomavirus positivity was detected in 43% of the patients with PCV in our study, which is slightly lower compared with previously reported data from meta-analyses (Smith et al, 2009 ) and other studies (Ferreira et al, 2008; Insinga et al, 2008; De Vuyst et al, 2009; Fuste et al, 2010; Brunner et al, 2011; Alonso et al, 2012; Larsson et al, 2013) , with a prevalence ranging between 51.4% and 81%. This variation is most likely due to differences in the detection methods used and in the selection of patients, but the geographical variation in HPV prevalence is another possibility. In the present study, HPV16 was the most prevalent type, as it was found in 63% of patients, which is in accordance with previous case series of patients with PCV (Fuste et al, 2010; Alonso et al, 2012; Larsson et al, 2013) , as well as patients with cervical and vulvar cancer. Other HPV types found were HPV18, 35, 45, 56, and 68, which are all considered as high-risk types, and are also occasionally found in other HPV-related cancers.
Studies on the spectrum of HPV types present in PCV are of particular importance with regard to the introduction of HPV vaccines, to evaluate their future effect on different diseases, including PCV. Larsson et al (2013) showed that HPV16-positive patients with PCV had better survival than those infected with other HPV types. In a study of patients with cervical carcinoma treated with radiotherapy, patients infected with HPV16, or other types from the alpha-9 species, had a more favourable prognosis (Wang et al, 2010; Lai et al, 2013) .
HPV16 is also the predominant type in oropharyngeal cancer. Human papillomavirus positivity has been shown to be a strong and independent prognostic factor of survival among patients with oropharyngeal cancer, and has been related to better response to chemoradiation (Lindquist et al, 2007; Ang et al, 2010; Marur et al, 2010; Gillison et al, 2012) . This could be attributed to different pathways of p53 dysfunction in HPV-positive and HPV-negative tumours (Crook et al, 1991) , but also to other cell cycle-related changes that could affect radiosensitivity (Pyeon et al, 2007) . Therefore, determination of HPV status is now part of routine diagnostic evaluation when assigning prognoses for these malignancies (Gillison et al, 2012) .
HPV18 is associated with less apoptosis than HPV16, which might result in increased radioresistance in HPV18-positive cervical tumours. A possible mechanism could be a difference in E6 oncoprotein activity (Arends et al, 1995; Hampson et al, 2001 ).
